Provided by Tiger Trade Technology Pte. Ltd.

PagerDuty, Inc.

12.25
-0.0700-0.57%
Volume:174.63K
Turnover:2.16M
Market Cap:944.75M
PE:5.78
High:12.45
Open:12.32
Low:12.22
Close:12.32
52wk High:17.29
52wk Low:5.70
Shares:77.12M
Float Shares:69.58M
Volume Ratio:1.06
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.12
EPS(LYR):1.87
ROE:94.62%
ROA:1.82%
PB:4.36
PE(LYR):6.55

Loading ...

PagerDuty Outlook FY Revenue USD 488.5-496.5 Million

THOMSON REUTERS
·
May 29

PagerDuty swings to FY27 Q1 profit of $10.2 million; revenue rises 1% year over year to $121 million

Reuters
·
May 29

PagerDuty Q1 Adj. EPS $0.32 Beats $0.25 Estimate, Sales $120.967M Beat $119.602M Estimate

Benzinga Earnings
·
May 29

PagerDuty Outlook Q2 Adj EPS $0.29 - $0.31

THOMSON REUTERS
·
May 29

PagerDuty - Appoints John Dilullo as CEO; Jennifer Tejada Transitions to Executive Chair

THOMSON REUTERS
·
May 29

PagerDuty - Announces $100 Mln Share Repurchase Program

THOMSON REUTERS
·
May 29

PagerDuty Outlook Q2 Total Revenue of $122.0 Mln - $124.0 Mln

THOMSON REUTERS
·
May 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 28

Supernus Pharmaceuticals to Participate in June Investor Conferences

GlobeNewswire
·
May 28

Annovis Bio Regains NYSE Listing Compliance

GlobeNewswire
·
May 26

Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026

GlobeNewswire
·
May 26

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

GlobeNewswire
·
May 22

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

GlobeNewswire
·
May 22

PagerDuty Executive Chair Jennifer Tejada disposes of common shares worth $3,227,879.12

Reuters
·
May 21

Press Release: Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants

Dow Jones
·
May 20

LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval

Stock News
·
May 19

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

GlobeNewswire
·
May 18

PagerDuty (PD) Gets a Hold from RBC Capital

TIPRANKS
·
May 16

Press Release: Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results

Dow Jones
·
May 15

Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 15